ALK-Abelló A/S (ALK-B.CO)

DKK 161.5

(5.56%)

Gross Profit Summary of ALK-Abelló A/S

  • ALK-Abelló A/S's latest annual gross profit in 2023 was 3.03 Billion DKK , up 8.74% from previous year.
  • ALK-Abelló A/S's latest quarterly gross profit in 2024 Q2 was 867 Million DKK , down -2.47% from previous quarter.
  • ALK-Abelló A/S reported a annual gross profit of 2.79 Billion DKK in annual gross profit 2022, up 16.49% from previous year.
  • ALK-Abelló A/S reported a annual gross profit of 2.39 Billion DKK in annual gross profit 2021, up 18.15% from previous year.
  • ALK-Abelló A/S reported a quarterly gross profit of 867 Million DKK for 2024 Q2, down -2.47% from previous quarter.
  • ALK-Abelló A/S reported a quarterly gross profit of 707 Million DKK for 2023 Q2, down -11.51% from previous quarter.

Annual Gross Profit Chart of ALK-Abelló A/S (2023 - 2002)

Historical Annual Gross Profit of ALK-Abelló A/S (2023 - 2002)

Year Gross Profit Gross Profit Growth
2023 3.03 Billion DKK 8.74%
2022 2.79 Billion DKK 16.49%
2021 2.39 Billion DKK 18.15%
2020 2.02 Billion DKK 7.19%
2019 1.89 Billion DKK 15.86%
2018 1.63 Billion DKK -0.55%
2017 1.64 Billion DKK -18.35%
2016 2.01 Billion DKK 16.04%
2015 1.73 Billion DKK 2.12%
2014 1.69 Billion DKK 9.7%
2013 1.54 Billion DKK -8.84%
2012 1.69 Billion DKK -2.3%
2011 1.73 Billion DKK 16.81%
2010 1.48 Billion DKK 10.31%
2009 1.34 Billion DKK 7.24%
2008 1.25 Billion DKK 9.02%
2007 1.15 Billion DKK 16.23%
2006 992 Million DKK 23.38%
2005 804 Million DKK 0.0%
2004 - DKK 0.0%
2003 - DKK 0.0%
2002 - DKK 0.0%

Peer Gross Profit Comparison of ALK-Abelló A/S

Name Gross Profit Gross Profit Difference
Bavarian Nordic A/S 4.52 Billion DKK 32.88%
Genmab A/S 16.24 Billion DKK 81.321%
Gubra A/S 114.93 Million DKK -2540.6%
Novo Nordisk A/S 196.49 Billion DKK 98.455%
Orphazyme A/S - DKK -Infinity%
Pharma Equity Group A/S -480 Thousand DKK 632391.667%
Zealand Pharma A/S 323.61 Million DKK -837.846%